Trial Profile
Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- 01 Dec 2015 New trial record